Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Cancer Research|July 20, 2006
Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agentsKlaus Mantwill, Nadia Köhler-Vargas, Alexandra Bernshausen, et al.
The Journal of Biological Chemistry|January 15, 2002
YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoterPer S Holm, Stephan Bergmann, Karsten Jurchott, et al.
Human Gene Therapy|June 20, 2018
The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder CancerEva Lichtenegger, Florestan Koll, Helena Haas, et al.
International Journal of Cancer|June 29, 2011
YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant gliomaRegina Holzmüller, Klaus Mantwill, Cornelia Haczek, et al.
International Journal of Molecular Sciences|September 9, 2022
The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse ModelMoritz Klawitter, Ali El-Ayoubi, Jasmin Buch, et al.
Cancer Research|January 20, 2004
Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapyPer S Holm, Hermann Lage, Stephan Bergmann, et al.
Nature Communications|August 10, 2022
Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirusJana Koch, Sebastian J Schober, Sruthi V Hindupur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2023
The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing SarcomaSebastian Johannes Schober, Caroline Schoening, Jennifer Eck, et al.
Pageof 2